###### 

Variables and examples from the iHARP database

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  iHARP variable                                            Example
  --------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient characteristics\                                  Question: About smoking: Which best describes you?\
   Age\                                                     Answers: Never smoked/used to smoke, but don't now/still smoking
   Sex\                                                     
   BMI\                                                     
   Level of education\                                      
   Year of asthma diagnosis\                                
   Age at asthma diagnosis\                                 
   Smoking status                                           

  Therapy\                                                  Paracetamol, ibuprofen, Gastro-oesophageal reflux disease prescription, ionotropics, anti-arrhythmic, anti-hypertensive, nitrates, β-adrenergic, oral β-blocker, topical β-blocker, cromolyn, nasal corticosteroids, topical corticosteroids, oral antihistamine, topical antihistamine
   Asthma\                                                  
   Non-asthma                                               

  Current control\                                          Question: In the last 7 days, how many days have you experienced asthma symptoms?
   Royal College of Physicians-3 (RCP-3)\                   
   Global Initiative for Asthma (GINA)\                     
   Asthma Therapy Assessment\                               
   Questionnaire (ATAQ)                                     

  Risk assessment over the last year\                       Question: In the last 12 months, how many times have you been treated in accident and emergency or anywhere other than your GP surgery for your asthma?
   Severe exacerbations\                                    
   Hospitalizations\                                        
   Accident and Emergency (A&E) visits\                     
   Days off work/education related to asthma                

  Comorbidities\                                            Connective tissue disorder, COPD, heart failure, myocardial infarction, tumor, peripheral vascular disease, ulcer, leukemia, dementia, mild liver disease, lymphoma, diabetes (type 1 or 2), hemiplegia, renal disease, severe liver disease, AIDS
   Individual comorbidities\                                
   Charlson Comorbidity Index score                         

  Rhinitis/allergies\                                       Question: Do you have any of these symptoms: itchy, runny, blocked nose or sneezing when you don't have a cold?\
   Rhinitis symptoms\                                       Answers: No/occasionally and little bother/occasionally and quite a bother/most days but little bother/most days and a lot of bother
   Rhinitis severity\                                       
   Allergies                                                

  Blood eosinophil count                                    Last recorded count in electronic medical records (UK only)

  Adherence to therapy\                                     Question: About your preventer inhaler-I use it only when I feel breathless\
   Medication Adherence Report Scale (MARS)                 Answers: Never to always on a 6 point scale

  Side effects with preventer inhaler\                      Continual sore throat, hoarse voice, oral thrush, abnormal weight gain, bruising, cough % peak expiratory flow or forced expiratory volume in 1 second at date of respiratory consultation
  Lung function                                             

  Inhaler technique\                                        Spirotrac inhalation timing and peak inspiratory flow rate assessment using empty placebo version of patient's device in the UK and Australia\
   HCP-assessed serious errors for devices:\                AIMS2 inhalation timing, flow rate and breath-hold assèssment set for patient's device type in the Netherlands, Spain, Italy, Sweden, Norway, and France
    DPI Diskus;\                                            
    DPI Turbuhaler^®^;\                                     
    MDI; or\                                                
    MDI with spacer\                                        
   Patient self-assessment\                                 
    Technology assessment including peak inspiratory flow   

  Fractional exhaled nitric oxide                           Recorded in PPB on date of respiratory consultation (UK only)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** iHARP, international implementing Helping Asthma in Real People; BMI, body mass index; HCP, health care practitioners; DPI, dry powder inhaler; MDI, metered dose inhaler; GP, general practitioner; AIM, aerosol inhalation monitor; PPB, parts per billion.

![Assessment of asthma control.](por-6-013Fig1){#f1-por-6-013}

###### 

Demographic characteristics and reasons for poor asthma control

  ----------------------------------------------------------------------------------------------------------------------------------
  Variable                       Category                   Low \<25 ppb\   Intermediate 25--50 ppb\   High \>50 ppb\   Total --\
                                                            n=523           n=139                      n=47             n=709
  ------------------------------ -------------------------- --------------- -------------------------- ---------------- ------------
  Sex: male n (%)                                           192 (36.7)      68 (48.9)                  24 (51.1)        284 (40.0)

  Age\                           18--30 years               35 (6.7)        11 (7.9)                   10 (21.3)        56 (7.9)
  n (%)                                                                                                                 

  31--50 years                   180 (34.4)                 46 (33.1)       13 (27.7)                  239 (33.7)       

  51--70 years                   288 (55.1)                 79 (56.8)       23 (48.9)                  390 (55.0)       

  \>70 years                     20 (3.8)                   3 (2.2)         1 (2.1)                    24 (3.4)         

  BMI, n (%)                     Underweight (BMI \<18.5)   6 (1.1)         0 (0.0)                    0 (0.0)          6 (0.8)

  Normal (BMI 18.5--24.99)       115 (22.0)                 38 (27.3)       16 (34.0)                  169 (23.8)       

  Overweight (BMI 25--29.99)     168 (32.1)                 49 (35.3)       15 (31.9)                  232 (32.7)       

  Obese (BMI ≥30)                234 (44.7)                 52 (37.4)       16 (34.0)                  302 (42.6)       

  Asthma Control\                Controlled (n=190)         147 (28.1)      32 (23.0)                  10 (21.3)        189 (26.7)
  n (%)                                                                                                                 

  Partially Controlled (n=313)   225 (43.0)                 66 (47.5)       20 (42.6)                  311 (43.9)       

  Uncontrolled (n=217)           151 (28.9)                 41 (29.5)       17 (36.2)                  209 (29.6)       
  ----------------------------------------------------------------------------------------------------------------------------------

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                              Category                                 Low \<25 ppb\   Intermediate 25--50 ppb\   High \>50 ppb\   Total --\
                                                                                 n=376           n=107                      n=37             n=520
  ------------------------------------- ---------------------------------------- --------------- -------------------------- ---------------- ------------
  **Reasons for poor asthma control**                                                                                                        

  Adherence\                            "I use it only when I feel breathless"   63 (16.8)       19 (17.8)                  9 (24.3)         91 (17.5)
  n (%)                                                                                                                                      

  "I avoid using it if I can"           52 (13.8)                                17 (15.9)       7 (18.9)                   76 (14.6)        

  "I forget to take it"                 59 (15.7)                                18 (16.8)       8 (21.6)                   85 (16.3)        

  "I decide to miss a dose"             44 (11.7)                                17 (15.9)       9 (24.3)                   70 (13.5)        

  "I choose to take it once a day"      97 (25.8)                                32 (29.9)       13 (35.1)                  142 (27.3)       

  Inhaler Technique\                    0 serious error                          120 (31.9)      29 (27.1)                  10 (27.0)        159 (30.6)
  (Serious Errors)\                                                                                                                          
  n (%)                                                                                                                                      

  1 serious error                       98 (26.1)                                26 (24.3)       9 (24.3)                   133 (25.6)       

  2+ serious error                      158 (42.0)                               52 (48.6)       18 (48.6)                  228 (43.8)       

  Comorbidities\                        0                                        327 (87.0)      98 (91.6)                  35 (94.6)        460 (88.4)
  (CCI)\                                                                                                                                     
  n (%)                                                                                                                                      

  1                                     26 (6.9)                                 5 (4.7)         0 (0.0)                    31 (6.0)         

  2                                     15 (4.0)                                 1 (0.9)         1 (2.7)                    17 (3.3)         

  ≥3                                    8 (2.1)                                  3 (2.8)         1 (2.7)                    12 (2.3)         

  Smoking status\                       Current Smoker                           64 (17.0)       8 (7.5)                    1 (2.7)          73 (14.0)
  n (%)                                                                                                                                      

  Ex-Smoker                             149 (39.6)                               42 (39.3)       8 (21.6)                   199 (38.3)       

  Non Smoker                            163 (43.4)                               57 (53.3)       28 (75.7)                  248 (47.7)       

  Courses of Steroids\                  0                                        261 (69.4)      72 (67.2)                  23 (62.2)        356 (68.4)
  n (%)                                                                                                                                      

  1                                     70 (18.6)                                20 (18.7)       6 (16.2)                   96 (18.5)        

  2+                                    45 (12.0)                                15 (14.0)       8 (21.6)                   68 (13.1)        

  Rhinitis\                             No Rhinitis                              115 (30.6)      30 (28.0)                  11 (29.7)        156 (30.0)
  n (%)                                                                                                                                      

  Mild Rhinitis                         191 (50.8)                               49 (45.8)       17 (45.9)                  257 (49.4)       

  Significant Rhinitis                  70 (18.6)                                28 (26.2)       9 (24.3)                   107 (20.6)       
  -------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BMI, body mass index; CCI, Charlson Comorbidity Index; ppb,.

###### 

Univariate association of truly serious errors with poor asthma control (uncontrolled versus controlled/partly controlled and uncontrolled/partly controlled versus controlled, defined by GINA) by device

  Outcome                                                                                GINA control (uncontrolled vs controlled/partly controlled)   GINA control (uncontrolled/partly controlled vs controlled)                        
  -------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- -------------------- ---------------
  **Diskus (n=884)**                                                                     **OR (95%CI)**                                                ***P*-value**                                                 **OR (95%CI)**       ***P*-value**
  Inhalation is not as long as you can                                                   1.90 (1.33--2.72)                                             \<0.001                                                       2.05 (1.38--3.09)    \<0.001
  No breath-hold                                                                         1.80 (1.29--2.50)                                             \<0.001                                                       2.10 (1.54--3.22)    \<0.001
  Inhalation is not forceful from the start                                              1.92 (1.35--2.71)                                             \<0.001                                                       1.47 (1.03--2.13)    0.038
  Inhalation is not as fast as you can                                                   1.64 (1.15--2.32)                                             0.006                                                         1.54 (1.07--2.25)    0.022
  Does not breath out slowly to empty lungs                                              1.48 (1.08--2.02)                                             0.015                                                         1.03 (0.76--1.40)    0.84
  Does not have head tilted such that chin is slightly upwards                           1.48 (1.09--2.02)                                             0.012                                                         1.65 (1.21--2.25)    0.002
  **Turbuhaler^®^ (n=2,220)**                                                            **OR (95%CI)**                                                ***P*-value**                                                 **OR (95%CI)**       ***P*-value**
  Does not remove cap                                                                    3.82 (1.00--15.48)                                            0.046                                                         3.67 (0.67--68.29)   0.220
  Shakes during preparation                                                              1.34 (1.01--1.75)                                             0.039                                                         1.28 (0.97--1.70)    0.080
  Device not held upright when the base is twisted during dose preparation               1.35 (1.11--1.65)                                             0.003                                                         1.27 (1.04--1.54)    0.016
  Dose not prepared correctly -- twisting the base until it clicks                       2.18 (1.34--3.49)                                             0.001                                                         1.80 (1.04--3.32)    0.045
  Dose not prepared correctly -- turn it back to the original position                   1.95 (1.29--2.88)                                             0.001                                                         2.27 (1.40--3.86)    0.001
  Device not held upright after the base is twisted until preparation                    1.73 (1.37--2.16)                                             \<0.001                                                       1.63 (1.29--2.08)    \<0.001
  Shakes after dose preparation                                                          2.06 (1.28--3.26)                                             0.002                                                         1.25 (0.76--2.13)    0.390
  Does not have head titled such that chin is slightly upward                            1.34 (1.09--1.63)                                             0.004                                                         1.51 (1.25--1.84)    \<0.001
  Inhalation is not as fast as you can                                                   1.86 (1.47--2.33)                                             \<0.001                                                       2.34 (1.80--3.08)    \<0.001
  Inhalation is not forceful from the start                                              1.87 (1.48--2.34)                                             \<0.001                                                       1.95 (1.52--2.53)    \<0.001
  Inhalation is not as long as you can                                                   1.59 (1.25--2.02)                                             \<0.001                                                       1.45 (1.13--1.88)    0.004
  No breath-hold                                                                         1.50 (1.20--1.87)                                             \<0.001                                                       1.35 (1.08--1.69)    0.008
  Second dose within 30 seconds                                                          1.39 (1.08--1.80)                                             0.009                                                         1.81 (1.34--2.47)    \<0.001
  Patient does not know the device is empty                                              1.82 (1.06--3.06)                                             0.025                                                         1.94 (1.06--3.84)    0.041
  **MDI (n=1,362)**                                                                      **OR (95%CI)**                                                ***P*-value**                                                 **OR (95%CI)**       ***P*-value**
  Does not breath out slowly to empty lungs                                              1.62 (1.25--2.10)                                             \<0.001                                                       1.54 (1.12--2.13)    0.009
  Does not hold inhaler upright                                                          1.51 (1.05--2.16)                                             0.025                                                         1.08 (0.72--1.68)    0.710
  Does not have head tilted such that chin is slightly upwards                           1.32 (1.04--1.68)                                             0.025                                                         1.24 (0.94--1.65)    0.130
  Actuation not corresponding to inhalation; actuation before inhalation                 1.38 (1.06--1.79)                                             0.017                                                         1.49 (1.09--2.08)    0.016
  No breath-hold                                                                         1.59 (1.26--2.02)                                             \<0.001                                                       1.32 (1.002--1.75)   0.051
  Second dose within 30 seconds                                                          1.37 (1.04--1.82)                                             0.026                                                         1.69 (1.19--2.45)    0.004
  **MDI (with spacer) (n=404)**                                                          **OR (95%CI)**                                                ***P*-value**                                                 **OR (95%CI)**       ***P*-value**
  Does not shake before placing into spacer                                              1.97 (1.28--3.03)                                             0.002                                                         1.48 (0.83--2.77)    0.200
  Does not breath out slowly to empty lungs                                              3.13 (1.95--5.02)                                             \<0.001                                                       1.47 (0.76--3.10)    0.280
  Does not actuate just one dose into the spacer                                         2.70 (1.38--5.32)                                             0.004                                                         1.23 (0.50--3.71)    0.680
  Does not have head tilted such that chin is slightly upwards                           1.70 (1.06--2.73)                                             0.028                                                         2.70 (1.26--6.71)    0.018
  Does not start to inhale through mouthpiece within 2 seconds of discharging one dose   2.22 (1.04--4.73)                                             0.036                                                         1.65 (0.56--7.07)    0.420
  No breath-hold                                                                         1.90 (1.20--3.0)                                              0.006                                                         1.05 (0.57--1.99)    0.890
  Second dose within 30 seconds                                                          1.72 (1.11--2.65)                                             0.015                                                         1.51 (0.84--2.86)    0.180
  No repeat second inhalation                                                            6.50 (1.47--44.82)                                            0.023                                                         1.25 (0.22--23.58)   0.840

**Abbreviations:** GINA, Global Initiative for Asthma; vs, versus; MDI, metered dose inhalers; OR, odds ratio; CI, confidence interval.

![Overall study design.\
**Notes:** \*Randomization into training. \*\*Randomization into assessment. ^≠^Are involved in the teaching of inhaler technique.\
**Abbreviation:** HCP, health care practitioners.](por-6-013Fig2){#f2-por-6-013}

###### 

Proportions of participants achieving device mastery for TH versus SP at each device training level at visit one

  Device training level   Number of participants =443   *P*-value (chi-squared test)   
  ----------------------- ----------------------------- ------------------------------ ---------
  Level 1                 31 (7)                        91 (21)                        \<0.001
  Level 2                 137 (31)                      240 (54)                       
  Level 3                 284 (64)                      320 (72)                       
  Level 4                 423 (96)                      429 (97)                       
  Level 5                 442 (100)                     442 (100)                      
  Level 6                 443 (100)                     443 (100)                      

**Abbreviations:** TH, Turbuhaler^®^; SP, Spiromax.

![Device preference by age group at baseline and week 12.](por-6-013Fig3){#f3-por-6-013}

###### 

Device preference (per-protocol population)

                                                Prefer BFS    Prefer BFT    No preference
  --------------------------------------------- ------------- ------------- ---------------
  Baseline, n (%)                               256 (47.7)    126 (23.5)    155 (28.9)
  (95% CI)                                      (0.43−0.52)   (0.20−0.27)   (0.25−0.33)
   *P*-value (in comparison to no preference)   \<0.0001      0.0836        
   *P*-value (in comparison to BFT)             \<0.0001                    
  Week 12, n (%)                                304 (56.6)    118 (22.0)    115 (21.4)
  (95% CI)                                      (0.52−0.61)   (0.18−0.25)   (0.18−0.25)
   *P*-value (in comparison to no preference)   \<0.0001      0.8442        
   *P*-value (in comparison to BFT)             \<0.0001                    

**Abbreviations:** BFS, budesonide-formoterol Spiromax; BFT, budesonide-formoterol Turbuhaler^®^; CI, confidence interval.

###### 

An excerpt from a patient report produced as part of the iHARP clinical review service

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                             Asthma review/patient response                                                                                                                                                                              Management feedback/recommendations
  -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Symptoms/Control           This patient's asthma is not completely under control                                                                                                                                                       The patient's responses indicate they are experiencing asthma symptoms that are impacting on daily life. These include:\
                                                                                                                                                                                                                                         • affected/woken by asthma symptoms at least once in the last week\
                                                                                                                                                                                                                                         • experienced asthma symptoms at least three times in the last week\
                                                                                                                                                                                                                                         • used reliever inhaler at least three times in the last week\
                                                                                                                                                                                                                                         • peak expiratory flow is less than 80% of predicted

  Risk/Exacerbations         The patient's responses indicate low risk due to 0 severe exacerbations in the past year                                                                                                                    This patient is low risk

  Treatment                  The patient's asthma appears to be uncontrolled on current therapy                                                                                                                                          • Consider stepping up asthma therapy as follows: (in line with BTS recommendations--step 4)--addition of high dose ICS (up to 2,000 mcg/day -- with concurrent LTRA and/or theophylline and/or long-acting β~2~-agonist\
                                                                                                                                                                                                                                         • Consider providing the patient with an asthma management plan -- BTS/NICE recommend that patients with asthma should be educated in the self-management of their disease

  Rhinitis                   The patient has poor asthma control and has indicated rhinitis as a problem on the questionnaire. Poorly controlled rhinitis is known to have a detrimental impact on asthma control                        Consider adding a leukotriene receptor antagonist for reported rhinitis symptoms

  Inhaler technique/errors   The review of the patient's inhaler technique has shown the following handling errors:\                                                                                                                     Provide patient education to review inhalation technique and inform the patient of all aspects of correct use of their device. Consider altering the patient's therapy to alternative formulations if the patient is not able to demonstrate improved performance on any error.
                             • puff 1--inhalation is not forceful from the start The review of the patient's inhalation flow has shown a pattern that is not consistent with good delivery of the medicine via the prescribed device:\   
                             • inhalation flow at 0.4s was recorded as 17 L/min. inhalation flow at 0.4s should be greater than 60 L/min                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ICS, inhaled corticosteroid; iHARP, international implementing Helping Asthma in Real People; min, minute; s, second; BTS: British Thoracic Society; LTRA, leukotriene receptor antagonist; NICE, National Institute for Health and Care Excellence.

###### 

Comparison of serious errors with PulmoJet versus Diskus, and PulmoJet versus Turbuhaler^®^, by patients naïve to both devices

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Device training                         Patients who made ≥1 serious error, n (%)   Odds ratio\                                                           *P*-value           
                                                                                      (95% confidence interval)[\*](#tfn7-por-6-013){ref-type="table-fn"}                       
  --------------------------------------- ------------------------------------------- --------------------------------------------------------------------- ------------------- ---------
  Patient information leaflet alone       167 (60)                                    203 (73)                                                              0.51 (0.34--0.75)   0.001

  Patient information leaflet and video   62 (22)                                     107 (39)                                                              0.31 (0.19--0.51)   \<0.001

                                          **PulmoJet**\                               **Turbuhaler**^®^\                                                                        
                                          (n=144)                                     (n=144)                                                                                   

  Patient information leaflet alone       85 (59)                                     119 (83)                                                              0.21 (0.10--0.43)   \<0.001

  Patient information leaflet and video   38 (26)                                     75 (52)                                                               0.23 (0.12--0.44)   \<0.001
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Odds ratio for serious error with PulmoJet relative to comparator device (1.00).

![Study design.\
**Note:** \*Ten percent drop-out during phase 1 and 24% of patients dropping out during phase 2 or not eligible for phase 2 due to exacerbations(s) in phase 1.](por-6-013Fig4){#f4-por-6-013}

![The distribution of patients across GOLD COPD categories A--D.](por-6-013Fig5){#f5-por-6-013}

###### 

Total health expenses (**A**), income from employment (**B**), and public transfer income (**C**) in Euros before and after diagnosis of COPD (green) compared with control participants (blue).

![](por-6-013Fig6)

![](por-6-013Fig6a)

###### 

Percentage of spouses of COPD patients (after diagnosis) and controls receiving various health care services and income

                                      Share   *P*-value   
  ------------------------------ ---- ------- ----------- --------
  Outpatient treatment           \%   37.3    34.8        \<0.01
  Inpatient treatment            \%   17.4    16.1        \<0.01
  Medication                     \%   86.8    84.5        \<0.01
  Public health insurance        \%   97.4    96.8        \<0.01
  Income from employment         \%   36.9    37.5        \<0.01
  Public transfer income total   \%   73.1    71.2        \<0.01
   Pension                       \%   46.7    47.1        \<0.01
   Other public transfers        \%   22.5    20.8        \<0.01
   Sick-pay (publicly funded)    \%   6.6     5.7         \<0.01

**Notes:** Bootstrapped Cochran-Armitage test showing whether the fraction received is significant, for each expense type. The values are given in percentages.

###### 

Outcome results (RR/OR and 95% CI) for extrafine versus standard-particle ICS

  Outcome (N=1,399 per group)                                                                                   EF-ICS         SP-ICS         *P*-value    EF vs SP-ICS (SP-ICS =1)                       
  ------------------------------------------------------------------------------------------------------------- -------------- -------------- ------------ -------------------------- ------------------- -------------------
  Number (%) of patients with ≥1 severe exacerbations[§](#tfn10-por-6-013){ref-type="table-fn"}                 163 (11.6)     270 (19.3)     \<0.001      0.59 (0.47, 0.73)          --                  
  Number (%) of patients achieving                                                                              1,236 (88.3)   1,129 (80.7)   \<0.001      --                         1.94 (1.57, 2.41)   
  Risk Domain Asthma Control[†](#tfn11-por-6-013){ref-type="table-fn"}                                                                                                                                    
  Number (%) of patients achieving Overall Asthma Control[†](#tfn11-por-6-013){ref-type="table-fn"}             1,091 (78.0)   934 (66.8)     \<0.001      --                         1.84 (1.55, 2.19)   
  Number (%) of patients achieving treatment stability[±](#tfn12-por-6-013){ref-type="table-fn"}                809 (57.8)     560 (40.0)     \<0.001      --                         2.11 (1.81, 2.46)   
  Number (%) of patients in each category of SABA daily dosage (μg)[¥](#tfn13-por-6-013){ref-type="table-fn"}   1--100         326 (23.3)     343 (24.5)   \<0.001                    --                  0.50 (0.44, 0.57)
  \>100                                                                                                         387 (27.7)     595 (42.5)                  --                                             

**Notes:** Adjusted for:

baseline severe exacerbations, prescriptions for proton-pump inhibitors and baseline asthma therapy.

Baseline RDAC/OAC, prescriptions for proton-pump inhibitors and asthma diagnosis.

Prescriptions for nasal steroid preparations and proton-pump inhibitors and baseline RDAC.

Odds ratio of higher versus lower dosage category, adjusted for baseline SABA daily dosage.

**Abbreviations:** ICS, inhaled corticosteroid; vs, versus; EF, extra-fine; SP, standard particles; RR, rate ratio; OR, odds ratio; CI, confidence interval; RDAC/OAC, Risk Domain Asthma Control/Overall Asthma Control; SABA, short-acting β-agonist.

###### 

Comparison of key characteristics of outcome versus baseline of patients changing from FP/SAL to FP/FOR

  Patient characteristics                                  Patients changing from FP/SAL to FP/FOR (N=153)   *P*-value                                                       
  -------------------------------------------------------- ------------------------------------------------- ------------- ------------------------------------------------- --------------------------------------------------
  Severe exacerbations                                     0, n (%)                                          116 (75.8)    121 (79.1)                                        0.218[‡](#tfn15-por-6-013){ref-type="table-fn"}
  1, n (%)                                                 24 (15.7)                                         24 (15.7)                                                       
  2+, n (%)                                                13 (8.5)                                          8 (5.2)                                                         
  Composite proxy asthma control                           Yes, n (%)                                        86 (56.2)     81 (52.9)                                         0.603[†](#tfn16-por-6-013){ref-type="table-fn"}
  LRTI consultations resulting in script for antibiotics   0, n (%)                                          91 (59.5)     83 (54.2)                                         0.398[‡](#tfn15-por-6-013){ref-type="table-fn"}
  1, n (%)                                                 35 (22.9)                                         41 (26.8)                                                       
  2+, n (%)                                                27 (17.6)                                         29 (19.0)                                                       
  SABA daily dose (μg)                                     Mean (SD)                                         2.3 (2.2)     2.3 (2)                                           0.957[\*](#tfn17-por-6-013){ref-type="table-fn"}
  Adherence to ICS                                         Mean (SD)                                         86.7 (39.1)   90.3 (35.4)                                       0.027[\*](#tfn17-por-6-013){ref-type="table-fn"}
  0%--70%, n (%)                                           51 (33.3)                                         41 (26.8)     0.006[†](#tfn16-por-6-013){ref-type="table-fn"}   
  71%--100%, n (%)                                         55 (35.9)                                         46 (30.1)                                                       
  101%--120%, n (%)                                        24 (15.7)                                         38 (24.8)                                                       
  121+%, n (%)                                             23 (15.0)                                         28 (18.3)                                                       

**Notes:**

Marginal homogeneity test;

McNemar Test;

Wilcoxon signed rank test.

**Abbreviations:** ICS, inhaled corticosteroid; FP/SAL, fluticasone-propionate/salmeterol; FP/FOR, fluticasone-propionate/formoterol; LRTI, lower respiratory tract infection; SABA, short-acting β-agonist; SD, standard deviation.

###### 

Baseline characteristics of patients switching from tiotropium to aclidinium bromide

  Patient characteristics                     Patients N=106   
  ------------------------------------------- ---------------- -----------
  Age at date of prescription, median (IQR)   69 (62,76)       
  Sex, n (%) male                             63 (59.4)        
  Current smokers, n (%)                      44 (41.9)        
  Body mass index, median (IQR), kg/m^2^      27.7 (24,32)     
  Comorbidities                               Asthma, n (%)    18 (16)
  Rhinitis diagnosis, n (%)                   15 (14.2)        
  Ischemic heart disease diagnosis, n (%)     27 (24.1)        
  Exacerbation (baseline), n (%)              0                62 (58.5)
  1                                           21 (19.8)        
  2+                                          23 (21.7)        
  Lung function severity, n (%)               Mild n (%)       7 (6.9)
  Moderate n (%)                              32 (31.4)        
  Severe n (%)                                30 (29.4)        
  Very severe n (%)                           33 (32.4)        
  GOLD group, n (%)                           A                19 (19.0)
  B                                           16 (16.0)        
  C                                           20 (20.0)        
  D                                           45 (45.0)        

**Abbreviation:** IQR, interquartile range.

###### 

Differences in ICS-adherence when using different definitions of the permissible gap in treatment episode calculation, follow-up time window, and method of adherence calculation

  Characteristic                                                                                       CMA4-method   CMA7-method                                                         
  ---------------------------------------------------------------------------------------------------- ------------- ------------- ------------- ------- -------- -------- ------------- -------
  **Full 2-year follow-up period**                                                                                                                                                       
  90-day gap[\*](#tfn20-por-6-013){ref-type="table-fn"}                                                13,922        24,924        88.9 (12.9)   78.8%   13,922   24,924   88.9 (12.9)   78.8%
  **Sensitivity analysis for permissible gap**                                                                                                                                           
  30-day gap                                                                                           13,922        38,339        97.3 (4.5)    99.0%   13,922   38,339   97.3 (4.5)    99.0%
  182-day gap                                                                                          13,922        18,603        79.7 (19.4)   55.3%   13,922   18,603   79.7 (19.4)   55.3%
  **Follow-up period by time interval, using 90-day gap[\$](#tfn21-por-6-013){ref-type="table-fn"}**                                                                                     
  0--12 months                                                                                         13,922        18,337        89.0 (14.8)   76.1%   13,922   18,337   89.0 (14.8)   76.1%
  12--24 months                                                                                        12,419        14,309        89.1 (15.6)   75.6%   12,419   14,218   87.2 (16.7)   71.4%
  0--6 months                                                                                          13,922        14,623        90.2 (15.5)   77.9%   13,922   14,623   90.2 (15.5)   77.9%
  6--12 months                                                                                         10,828        10,942        92.1 (15.0)   82.7%   10,828   10,938   87.3 (18.4)   72.0%
  12--18 months                                                                                        10,635        10,752        92.4 (14.5)   83.5%   10,635   10,744   87.2 (18.2)   71.5%
  18--24 months                                                                                        11,267        11,759        90.3 (15.7)   78.4%   10,444   10,552   87.5 (18.4)   72.7%
  0--8 months                                                                                          13,922        15,732        89.6 (15.5)   76.7%   13,922   15,732   89.6 (15.5)   76.7%
  8--16 months                                                                                         11,479        12,041        89.9 (15.8)   77.5%   11,479   12,000   87.0 (17.5)   70.8%
  16--24 months                                                                                        11,267        11,759        90.3 (15.7)   78.4%   11,267   11,723   87.4 (17.9)   72.2%

**Notes:**

Permissible gap between end date of prescription and start date of next prescription in calculation of treatment episodes.

Full follow-up period divided in smaller time windows, using the 90-day permissible gap in calculation of treatment episodes.

**Abbreviations:** ICS, inhaled corticosteroid; SD, standard deviation.
